Acusphere

Acusphere Quick Ratio

The Quick Ratio (Acid Test) of Acusphere (ACUS) as of Oct 4, 2026 is 0.03. In the previous year, Quick Ratio (Acid Test) was 1.04 — a change of -97.37% (lower).

Quick Ratio

0.03

YoY

-97.37%

Last updated:

Quick Ratio (Acid Test) of Acusphere is 2026 0.03 . Quick Ratio (Acid Test) of Acusphere was 2025 1.04 . It decreases by -97.37% lower compared to the previous year.
Access this data via the Eulerpool API

Acusphere Stock analysis

What does Acusphere do? Acusphere Inc is a US-American company that was founded in 1993. It specializes in the development and marketing of advanced pharmaceuticals and therapeutic platforms in the fields of cardiology and pulmonology. The company is based in Lexington, Massachusetts and currently employs about 30 employees. The history of Acusphere goes back to the discovery of a new class of pharmaceutical agents, called microspheres. These spherical particles have a diameter of only a few micrometers and can have the ability to bind various therapeutic agents and release them in a targeted manner in the body. Acusphere has developed several innovative products and technologies based on these microspheres in recent years. One focus of the company is the development of therapies for patients with cardiovascular diseases such as heart failure or coronary artery disease. Another research area of ​​the company is the development of therapies for patients with lung diseases such as COPD or asthma. The business model of Acusphere is mainly based on the discovery and marketing of new drugs and therapies. In order to achieve these goals, the company works closely with leading scientific institutions and invests a significant portion of its budget in research and development. Acusphere is divided into several business areas, each of which includes different products and technologies. One of the most important business areas is the development of drugs for the treatment of cardiovascular diseases. An example of this is the drug EchoSphere, which was developed based on microspheres and is able to improve the oxygen supply to the heart muscle. Another important business area of ​​Acusphere is the development of products for the treatment of lung diseases such as COPD and asthma. For this purpose, the company has developed several new technologies that allow targeted delivery of medication to the lungs and its effects there. One of these technologies is the so-called Solutol technology, which allows medication to be concentrated in the alveoli of the lungs while avoiding unwanted side effects. In recent years, Acusphere has developed a number of innovative products and technologies that have great market potential due to their high efficacy and tolerability. The company is making every effort to bring these products to the market as quickly as possible and make a significant contribution to improving healthcare. Acusphere is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Acusphere stock

Quick Ratio (Acid Test) of Acusphere is 0.03 in 2026.

Quick Ratio (Acid Test) of Acusphere changed from 1.04 to 0.03, representing a -97.37% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Quick Ratio (Acid Test) Acusphere since 2006 – with annual values, charts, and detailed analysis.

The Quick Ratio measures liquidity by comparing liquid assets to current liabilities, excluding inventory. It is a more conservative measure than the current ratio.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Quick Ratio (Acid Test)'s Acusphere with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Leverage — Acusphere

All Key Metrics — Acusphere